Thomas Schlange received his Diploma in Chemistry in 1998 and his PhD in 2003 at the Technical University Braunschweig, Germany. His research was focused on BMP/Activin signalling in early cardiac development. From 2003 until 2008 he worked as a postdoctoral fellow at the Friedrich Miescher Institute in Basel, Switzerland, on Wnt and EGFR signalling in breast cancer. Since 2008 Thomas Schlange is scientist with Bayer Pharma AG in Wuppertal, Germany, leading projects in anti-angiogenesis/oncology and ophthalmology research and is responsible for biomarker projects/strategy in lung diseases. He is the EFPIA coordinator of the Innovative Medicines Initiative (IMI) consortium CANCER-ID (www.cancer-id.eu). CANCER-ID aims to evaluate technologies for enrichment, isolation and analysis of Circulating Tumor Cells (CTCs), circulating free tumor DNA (ctDNA) and microRNAs (miRNAs) as biomarkers for cancer liquid biopsy.